EC approves Roche`s juvenile arthritis drug – PMLiVE

August 8, 2011 by  
Filed under Osteo-Arthritis News

EC approves Roche's juvenile arthritis drug
PMLiVE
The European Commission has approved the use of Roche's RoACTEMRA (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients two years of age and older who have responded inadequately to previous therapies.
Roche's RoACTEMRA approved in Europe for children living with a rare and PipelineReview.com (press release)
Roche gets EU approval for RoActemra for children with rare form of arthritisThe Pharma Letter
Roche gets European approval for RoACTEMRAZenopa

all 3 news articles »

More Info: Click here

“Finally, you can have the same Revolutionary Yoga Program top athletes use for TOTAL mind-body fitness ... in just 30 minutes a day!”

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!

This blog is kept spam free by WP-SpamFree.

Access denied for user ''@'localhost' (using password: NO)